Dr. Chain is a seasoned biotechnology executive, innovator and scientist-entrepreneur who has spearheaded the development of innovative therapeutics for the treatment of neurodegenerative diseases. For more than 20 years, he has established and managed companies in this field, including Mindset Biopharmaceuticals, Intellect Neurosciences, and CereSpir, and his patented innovations helped enable the development of monoclonal antibodies tested in late-stage clinical trials for Alzheimer’s disease by global pharmaceutical companies. Dr. Chain obtained his PhD in Biochemistry from the Weizmann Institute of Sciences in Israel and was a Howard Hughes postdoctoral research fellow in the Center for Neurobiology and Behavior at Columbia University in New York.
Daniel G. Chain, PhD – President and Chief Executive Officer
Richard A. Margolin, MD - Senior Vice President of Translational Sciences and Clinical Development
Dr. Margolin is a physician-scientist trained in psychiatry and nuclear medicine with extensive academic and pharmaceutical industry experience. Previously, he was Executive Director, Clinical Neuroscience and Interim Alzheimer’s Disease Clinical Head, Internal Medicine Research Unit at Pfizer. Earlier, he held positions at CereSpir, Janssen Alzheimer Immunotherapy, Schering-Plough/Merck, and i3 Research. Prior to working in the pharmaceutical industry, Dr. Margolin built and directed the Division of Geriatric Psychiatry at Vanderbilt University and later led the University of Southern California’s Consultation-Liaison Psychiatry Division. Dr. Margolin received an AB degree from Harvard College magna cum laude and an MD degree from the University of California, Irvine. He has authored or co-authored approximately 60 scientific publications and has spoken widely on challenges and opportunities in drug development for neurodegenerative diseases.